Production of limit size nanoliposomal systems with potential utility as ultra-small drug delivery agents

Journal of Liposome Research

Volumn 26, Issue 2, 2016, Pages 96-102

  Zhigaltsev, Igor V ^a   Tam, Ying K ^a   Leung, Alex K K ^a   Cullis, Pieter R ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Doxorubicin; herringbone micromixer; limit size nanoparticles; liposome; microfluidic mixing

Indexed keywords

1 PALMITOYL 2 OLEOYL PHOSPHATIDYLCHOLINE; CARBON 14; CHOLESTEROL; DIPALMITOYLPHOSPHATIDYLCHOLINE; DOXORUBICIN; LIPID NANOPARTICLE; MACROGOL 2000; NANOCARRIER; PHOSPHATIDYLCHOLINE; UNCLASSIFIED DRUG; DRUG CARRIER; LIPID; LIPOSOME; NANOPARTICLE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG MANUFACTURE; DRUG RETENTION; FEMALE; IN VITRO STUDY; IN VIVO STUDY; LIPID COMPOSITION; MICROFLUIDIC MIXING; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; ANIMAL; BLOOD; CHEMISTRY; DRUG DELIVERY SYSTEM; SURFACE PROPERTY;

ANIMALS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; LIPIDS; LIPOSOMES; MICE; NANOPARTICLES; PARTICLE SIZE; SURFACE PROPERTIES;

EID: 84961185305     PISSN: 08982104     EISSN: 15322394     Source Type: Journal    
DOI: 10.3109/08982104.2015.1025411     Document Type: Article

References (31)

1. Allen TM, Hansen C, Martin F, et al. (1991). Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim Biophys Acta 1066:29-36.
2. Bally MB, Nayar R, Masin D, et al. (1990). Liposomes with entrapped doxorubicin exhibit extended blood residence times. Biochim Biophys Acta 1023:133-9.
3. Batzri S, Korn ED. Single bilayer liposomes prepared without sonication. (1973). Biochim Biophys Acta 298:1015-19.
4. Belliveau NM, Huft J, Lin PJ, et al. (2012). Microfluidic synthesis of highly potent limit-size lipid nanoparticles for in vivo delivery of siRNA. Mol Ther Nucleic Acids 1:e37.
5. Cabral H, Matsumoto Y, Mizuno K, et al. (2011). Accumulation of sub- 100 nm polymeric micelles in poorly permeable tumours depends on size. Nat Nanotechnol 6:815-23.
6. Chen S, Tam YYC, Lin PJC, et al. (2014). Development of lipid nanoparticle formulations of siRNA for hepatocyte gene silencing following subcutaneous administration. J Conrol Release 196:106-12.
7. Charrois GJ, Allen TM. (2004). Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer. Biochim Biophys Acta 1663:167-77.
8. Chauhan VP, Jain RK. (2013). Strategies for advancing cancer nanomedicine. Nat Mater 12:958-62.
9. Chauhan VP, Stylianopoulos T, Boucher Y, Jain RK. (2011). Delivery of molecular and nanoscale medicine to tumors: transport barriers and strategies. Annu Rev Chem Biomol Eng 2:281-98.
10. De Kruijff B, Cullis PR, Radda GK. (1975). Differential scanning calorimetry and 31P NMR studies on sonicated and unsonicated phosphaditylcholine liposomes. Biochim Biophys Acta 406:6-20.
11. Dreher MR, Liu W, Michelich CR, et al. (2006). Tumour vascular permeability, accumulation, and penetration of macromolecular drug carriers. J Natl Cancer Inst 98:330-43.
12. Gabizon AA. (2002). Liposomal drug carrier systems in cancer chemotherapy: current status and future prospects. J Drug Target 10:535-8.
13. Green MR, Manikhas GM, Orlov S, et al. (2006). Abraxane-, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. Ann Oncol 8: 1263-8.
14. Haran G, Cohen R, Bar LK, Barenholz Y. (1993). Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphiphathic weak bases. Biochim Biophys Acta 1151: 201-15.
15. Hope MJ, Bally MB, Mayer LD, et al. (1986). Generation of multilamellar and unilamellar phospholipid vesicles. Chem Phys Lipids 40:89-108.
16. Huang C. (1969). Phosphatidylcholine vesicles. Formation and physical characteristics. Biochemistry 8:344-52.
17. Huo S, Ma H, Huang K, et al. (2013). Superior penetration and retention behavior of 50 nm gold nanoparticles in tumors. Cancer Res 73: 319-30.
18. Jahn A, Stavis SM, Hong JS, et al. (2010). Microfluidic mixing and the formation of nanoscale lipid vesicles. ACS Nano 4:2077-87.
19. Jahn A, Vreeland WN, DeVoe DL, et al. (2007). Microfluidic directed formation of liposomes of controlled size. Langmuir 23:6289-93.
20. Jain RK, Stylianopoulos T. (2010). Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol 7:653-64.
21. Johnston MJ, Edwards K, Karlsson G, Cullis PR. (2008). Influence of drug-to-lipid ratio on drug release properties and liposome integrity in liposomal doxorubicin formulations. J Liposome Res 18:145-57.
22. Kano M, Bae Y, Iwata C, et al. (2007). Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumours by inhibition of TGF-b signaling. Proc Natl Acad Sci 104:3460-5.
23. Maeda H, Wu J, Sawa T, et al. (2000). Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 65:271-84.
24. Mayer LD, Tai LC, Ko DSC, et al. (1989). Influence of vesicle size, lipid composition and drug-to-lipid ratio on the biological activity of liposomal doxorubicin. Cancer Res 49:5922-30.
25. Perrault SD, Walkey C, Jennings T, et al. (2009). Mediating tumour targeting efficiency of nanoparticles through design. Nano Lett 9: 1909-15.
26. Semple SC, Chonn A, Cullis PR. (1996). Influence of cholesterol on the association of plasma proteins with liposomes. Biochemistry 35: 2521-5.
27. Silverman JA, Deitcher SR. (2013). Marqibo® (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine. Cancer Chemother Pharmacol 71:555-64.
28. Unezaki S, Maruyama K, Nagae I, et al. (1996). Direct measurement of the extravasation of polyethyleneglycol-coated liposomes into solid tumor tissue by in vivo fluorescence microscopy. Int J Pharm 144: 11-17.
29. Uster PS, Working PK, Vaage J. (1998). Pegylated liposomal doxorubicin (DOXIL®, CAELYX®) distribution in tumour models observed with confocal laser scanning microscopy. Int J Pharm 162:77-86.
30. Zhigaltsev IV, Belliveau N, Hafez I, et al. (2012). Bottom-up design and synthesis of limit size lipid nanoparticle systems with aqueous and triglyceride cores using millisecond microfluidic mixing. Langmuir 28:3633-40.
31. Zhigaltsev IV, Maurer N, Edwards K, et al. (2006). Formation of drugarylsulfonate complexes inside liposomes: a novel approach to improve drug retention. J Control Release 110:378-86.